|
EC 5.4.3.* (intramolecular transferase transferring amino groups) inhibitor
|
CHEBI_76829 |
|
|
rosuvastatin
|
CHEBI_38545 |
|
|
EC 3.2.1.31 (beta-glucuronidase) inhibitor
|
CHEBI_76822 |
|
|
EC 5.1.1.* (racemases acting on amino acids and derivatives) inhibitor
|
CHEBI_76828 |
|
|
distributed
|
PATO_0001566 |
|
|
chikungunya
|
DOID_0050012 |
|
|
one-hybrid assay
|
BAO_0002490 |
|
|
hybrid screening
|
BAO_0002489 |
|
|
three-hybrid assay
|
BAO_0002491 |
|
|
two-hybrid assay
|
BAO_0002492 |
|
|
carbohydrate metabolism disease
|
DOID_0050013 |
|
|
acquired metabolic disease
|
DOID_0060158 |
|
|
osteoarthritis
|
DOID_8398 |
|
|
anti-inflammatory agent
|
CHEBI_67079 |
|
|
propidium iodide exclusion
|
BAO_0002482 |
|
|
dye exclusion method
|
BAO_0002481 |
|
|
EC 2.3.3.8 (ATP citrate synthase) inhibitor
|
CHEBI_149598 |
|
|
EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor
|
CHEBI_77022 |
|
|
vital staining of cells
|
BAO_0002483 |
|
|
vital dye staining
|
BAO_0002480 |
|
